Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297292 | 1.00 | THRB (0.44) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL94668 | 1.00 | THRB (0.44) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL28623616 | 0.98 | THRB (0.43) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL612356 | 0.90 | TSHR (0.49) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL16243745 | 0.90 | TSHR (0.49) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL28297110 | 0.89 | TSHR (0.47) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL611316 | 0.89 | TSHR (0.51) | THRBTSHRKDM4EPOLBAPEX1 | |
| SCHEMBL9902707 | 0.80 | THRB (0.42) | THRBTSHRPOLBAPEX1HTT | |
| SCHEMBL9410884 | 0.77 | KDM4E (0.39) | TSHRKDM4E | |
| SCHEMBL6029952 | 0.77 | ALDH1A1 (0.48) | THRBTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109844052-B | Adhesive composition for protective film and protective film | 日本电石工业株式会社 | 2021-11-23 | — | — | CN | disclosed |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2018-07-05 | — | — | US | disclosed |
| US-9957271-B2 | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9177819-B2 | Method for manufacturing silicon substrate having textured structure | TOKUYAMA CORPORATION (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140349485-A1 | METHOD FOR MANUFACTURING SILICON SUBSTRATE HAVING TEXTURED STRUCTURE | TOKUYAMA CORPORATION a corporation | 2014-11-27 | — | — | US | disclosed |
| US-20080124456-A1 | Inkjet ink and method for forming cured film using the same | CHISSO CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | THRB 1348/4885TSHR 1906/4885KDM4E 564/4885 |
| US-20180186801-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | THRB 1348/4885TSHR 1906/4885KDM4E 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.